Common Contracts
2 similar Licensing, Supply, Marketing, Distribution and Collaboration Agreement contracts by Osmotica Pharmaceuticals LTD, Osmotica Pharmaceuticals PLC
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Fifth Amendment to the Licensing, Supply,...Licensing, Supply, Marketing, Distribution and Collaboration Agreement • September 14th, 2018 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations
This fifth amendment (the “Fifth Amendment”), effective as of the 1st day of January, 2018, amends the Licensing, Supply, Marketing, Distribution and Collaboration Agreement dated effective as of November 24, 2003 (the “Agreement”), as amended by the First Amendment dated May 20, 2004, the Second Amendment dated June 30, 2004, the Third Amendment dated May 20, 2010 and the Fourth Amendment dated August 1, 2013 (the Agreement and the amendments are collectively referred to as the “Amended Agreement”), by and between Upsher-Smith Laboratories, Inc. (“USL”), and Orion Corporation (“Orion”). The Amended Agreement was assigned to Vertical Pharmaceuticals, LLC (“Vertical”) by USL, effective as of March 24, 2014. Capitalized terms appearing in this Fifth Amendment not defined herein have the meaning given to them in the Amended Agreement.
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Fifth Amendment to the Licensing, Supply,...Licensing, Supply, Marketing, Distribution and Collaboration Agreement • May 9th, 2018 • Osmotica Pharmaceuticals LTD • Pharmaceutical preparations
This fifth amendment (the “Fifth Amendment”), effective as of the 1st day of January, 2018, amends the Licensing, Supply, Marketing, Distribution and Collaboration Agreement dated effective as of November 24, 2003 (the “Agreement”), as amended by the First Amendment dated May 20, 2004, the Second Amendment dated June 30, 2004, the Third Amendment dated May 20, 2010 and the Fourth Amendment dated August 1, 2013 (the Agreement and the amendments are collectively referred to as the “Amended Agreement”), by and between Upsher-Smith Laboratories, Inc. (“USL”), and Orion Corporation (“Orion”). The Amended Agreement was assigned to Vertical Pharmaceuticals, LLC (“Vertical”) by USL, effective as of March 24, 2014. Capitalized terms appearing in this Fifth Amendment not defined herein have the meaning given to them in the Amended Agreement.
